Evidence map›Paper›PMID 39572200›Full record

ArticleAJNR. American journal of neuroradiology2025

[

Samir A Dagher, Kim O Learned, Richard Dagher, Jennifer Rui Wang, Xiao Zhao, S Mohsen Hosseini, Anastasios Maniakas, Maria E Cabanillas, Naifa L Busaidy, Ramona Dadu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Samir A DagherFrom the Department of Neuroradiology/Head and Neck Imaging (S.A.M., K.O.L., R.D., A.M.K), The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0003-0155-7444
Kim O LearnedFrom the Department of Neuroradiology/Head and Neck Imaging (S.A.M., K.O.L., R.D., A.M.K), The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-5125-4022
Richard DagherFrom the Department of Neuroradiology/Head and Neck Imaging (S.A.M., K.O.L., R.D., A.M.K), The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0009-0001-7666-2989
Jennifer Rui WangDepartment of Head and Neck Surgery (J.R.W., X.Z., A.M., M.E.Z.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xiao ZhaoDepartment of Head and Neck Surgery (J.R.W., X.Z., A.M., M.E.Z.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
S Mohsen HosseiniDepartment of Pathology (S.M.H.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anastasios ManiakasDepartment of Head and Neck Surgery (J.R.W., X.Z., A.M., M.E.Z.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-5124-1811
Naifa L BusaidyDepartment of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ramona DaduDepartment of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Priyanka IyerDepartment of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mark E ZafereoDepartment of Head and Neck Surgery (J.R.W., X.Z., A.M., M.E.Z.), The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0001-7918-9739
Alexander M KhalafFrom the Department of Neuroradiology/Head and Neck Imaging (S.A.M., K.O.L., R.D., A.M.K), The University of Texas MD Anderson Cancer Center, Houston, Texas AKhalaf@mdanderson.org.ORCID https://orcid.org/0000-0001-6366-6318

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeNeoadjuvant MATERIALS AND

methodsThis retrospective, single-center study included consecutive

resultsThirty patients (mean age 66.5 ± 9.0; 17 men) were included in this study, with 94 surgically sampled lesions. Of these lesions, 57 (60.6%) were low-risk (39 negative, 18 papillary thyroid carcinoma) and 37 (39.4%) were high-risk (29 ATC, 8 PDTC). FDG uptake was higher for high-risk compared with low-risk pathologies: median SULmax 5.01 (interquartile range [IQR] 2.81-10.95) versus 1.29 (IQR 1.06-3.1) (

conclusionsPreoperative FDG-PET noninvasively identifies lesions with residual high-risk pathologies following neoadjuvant

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyProto-Oncogene Proteins B-rafThyroid Carcinoma, AnaplasticThyroid NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm, ResidualRadiopharmaceuticalsRetrospective StudiesBRAF protein, humanFluorodeoxyglucose F18Proto-Oncogene Proteins B-rafRadiopharmaceuticals

Identifiers

PMID39572200
PMCPMC12152800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.